Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that
It has been more than four years since the UK left the EU, but the government is still being forced to delay the introduction of border control rules that could have conse
The biopharma industry faces a relentless demand for evidence of real-world effectiveness (RWE), safety, and value throughout the product lifecycle to complement the clinical trial-based be
Moderna’s efforts to develop a range of mRNA vaccines for influenza have been bolstered with funding of up to $750 million from investment firm Blackstone Life Sciences.
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.